Phosphoantigen-sensitive Vg9Vd2 T cells are important responders to infections and malignancy. However, the mechanisms by which phosphoantigens stimulate Vg9Vd2 T cells are unclear. Here, we synthesized phosphoantigen prodrugs and used them to demonstrate that intracellular delivery of phosphoantigens is required for their activity. The pivaloyloxymethyl prodrug is the most potent phosphoantigen described to date, with stronger stimulation of Vg9Vd2 T cells from human peripheral blood and greater ability to induce lysis of Daudi lymphoma cells relative to the previously most potent compound, (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP). We demonstrate high binding affinity between phosphoantigens and the intracellular region of butyrophilin 3A1 (BTN3A1), localized to the PRY/SPRY (B30.2) domain, but also affecting the membrane proximal region. Our findings promote a phosphoantigen prodrug approach for cancer immunotherapy and unravel fundamental aspects of the mechanisms of Vg9Vd2 T cell activation.
INTRODUCTION
The cells of the immune system recognize diverse foreign-and self-antigens, generating responses that remove a variety of foreign invaders with great specificity. As such, generation of drug-like molecules that can regulate immune cell function is of wide interest. The gd T cells, usually only comprising 1%-10% of circulating T cells, have received attention recently due to their function in cancer immunosurveillance (Bonneville et al., 2010) . Unlike the ab T cells that respond to peptides, a subset of gd T cells (Vg9Vd2 T cells) detects small phosphorouscontaining compounds (phosphoantigens) (Wiemer and Wiemer, 2014) . The Vg9Vd2 T cells most likely gained sensitivity to phosphoantigens to fight bacterial infections, given that the most potent natural phosphoantigen, (E)-4-hydroxy-3-methyl-but-2-enyl diphosphate (HMBPP) is produced by bacteria, but not humans (Morita et al., 2007) . However, phosphoantigen-activated cells also can suppress viruses and malignancies (Gao et al., 2003; Wang et al., 2006) .
Phosphoantigens such as HMBPP are detected by the Vg9Vd2 T cell receptor after binding to butyrophilin 3A1 (BTN3A1) (Harly et al., 2012; Wang et al., 2013) through major histocompatibility complex-independent mechanisms that are not yet completely clear. Both intracellular and extracellular binding of BTN3A1 to phosphoantigens have been recently reported (Sandstrom et al., 2014; Vavassori et al., 2013) . Once activated, Vg9Vd2 T cells eliminate phosphoantigen-loaded target cells through killer cell lectin-like receptor subfamily K, member 1 receptor signaling and perforin release (Wrobel et al., 2007) and recruit other immune cells via chemokine production (Li et al., 2005 (Li et al., , 2013 . Therefore, development of compounds that can bind to BTN3A1 in cancer cells to promote their lysis by Vg9Vd2 T cells may be a promising anticancer strategy. However, questions remain about how to best target phosphoantigens to their cellular binding site.
Prodrug approaches increasingly are applied to compounds employed in antiviral and antitumor therapy (Hecker and Erion, 2008) . The majority of prodrug applications of phosph(on)ates seek to facilitate passive diffusion through the cell membrane by masking negative charge until the compound is within the cell, eliminating the need for endocytic uptake. Because small, highly charged molecules can exhibit low membrane permeability (Kornberg et al., 1972) , synthesis of protected compounds such as pivaloyloxymethyl (POM) derivatives (e.g., Adefovir dipivoxil) (Cundy, 1999; De Clercq, 2004; Marcellin et al., 2003) has been used to advance such molecules to clinical use. We hypothesized that an analogous strategy could be utilized to determine the role of cellular entry in phosphoantigen-induced T cell activation. Upon diffusion into the cell, the protecting groups from a phosphoantigen prodrug are thought to be released by cellular esterases, leaving an anionic phosphoantigen inside the cells. If intracellular/cytoplasmic binding to BTN3A1 is required for phosphoantigen activity, one might expect this strategy to increase potency relative to the free phosphoantigen anion, because the negatively charged phosphoantigen should not transverse the cell membrane as readily.
With this in mind, we developed a synthetic route to make POM-protected phosphoantigens and examined the activity of these compounds in Vg9Vd2 T cell activation. Here, we demonstrate that a POM-protected phosphoantigen is a highly potent Vg9Vd2 T cell stimulus, which effectively delivers the phosphoantigen to the intracellular binding site of BTN3A1. The compound, while nontoxic on its own, induces potent killing of malignant cells by Vg9Vd2 T cells, which could ultimately lead to a new class of cancer immunotherapy agents.
RESULTS

Synthesis of a Phosphoantigen and Its
Pivaloyloxymethyl-Protected Prodrug Vg9Vd2 T cells can be activated by direct phosphoantigens such as HMBPP, which can occur at low nanomolar concentrations, and indirect phosphoantigens such as the nitrogenous bisphosphonates, for which activation occurs at micromolar concentrations and is dependent upon their ability to increase the concentration of the direct phosphoantigen isopentenyl diphosphate (IPP) (Sicard et al., 2005) (Figure 1 ). However, diphosphates such as HMBPP have poor pharmacokinetic properties, most notably rapid clearance from the plasma due to phosphatase-mediated degradation and low membrane permeability due to the negative charges of the acidic oxygen atoms at physiological pH (Sicard et al., 2005) . Therefore, we chose to generate a series of prodrug compounds based on the more stable phosphonate substructure (i.e., compound 1a).
We have previously developed synthetic routes to make POM-protected bisphosphonates, which dramatically enhance cellular activity (Wiemer et al., 2008) . To initiate the current synthetic pathway, we prepared the key phosphonate salt (compound 1a) and the corresponding POM-modified compounds 1b and 1c (Figure 2 ). Phosphonate 1a was chosen as our initial target because it has good chemical stability (decreasing the possibility of phosphatase metabolism) and is a modest phosphoantigen (Boë dec et al., 2008) . However, to secure an efficient preparation of the parent structure as both the disodium salt 1a and as the POM-protected compounds 1b and 1c, we developed the synthetic sequence shown in Figure 2 . Thus after preparation of prenyl bromide 3 from alcohol 2, this allylic halide was allowed to react with the anion of dimethyl methylphosphonate to afford the phosphonate 4. Compound 4 was oxidized upon treatment with selenium dioxide, and then the E alcohol 1d was isolated after treatment with NaBH 4 to reduce any aldehyde, using procedures we had applied earlier to preparation of geranyl (Kim et al., 2004) and then prenyl (Maalouf et al., 2007) derivatives. Hydrolysis of compound 1d under standard conditions (McKenna et al., 1977) gave the expected sodium salt 1a in good Compounds evaluated in this study include the control phosphoantigens (HMBPP, IPP, and risedronate) and the phosphonate (1a), and its protected counterparts (1b, 1c, and 1d).
yield. Unfortunately, use of compound 1d to prepare compound 1b proved problematic. Because reaction at the hydroxyl group proved to be competitive, a slightly modified sequence was employed to reach compound 1b. Phosphonate 4 first was converted to the bis-POM analog 6. While some of the mono-POM mono-methyl ester 7 also was formed, this was not a significant complication because the two compounds were readily separable by column chromatography. Reaction of compound 6 with selenium dioxide gave the POM-protected target 1b in modest yield. Compound 7 then was treated independently with selenium dioxide to obtain the closely related compound 1c. Reduction with borohydride was avoided to minimize potential decomposition of the POM groups.
Pivaloyloxymethyl-Protected Phosphoantigens Potently Stimulate Human Peripheral Blood Vg9Vd2 T Cells
We evaluated compounds 1a and 1b for their ability to stimulate Vg9Vd2 T cell proliferation ( Figure 3A) . Peripheral blood mononuclear cells (PBMCs) derived from healthy donors were incubated with 1 mM of compound 1a or 1b for 3 days in the presence of interleukin 2 (IL-2). Cells were examined for the proportion of cluster of differentiation 3 (CD3)+ Vg9Vd2 T cells in live cultures 2 weeks post stimulation by flow cytometry. As expected, treatment with HMBPP (58.5% ± 1.8%) significantly expanded the population of Vg9Vd2 T cells as compared to cells treated with IL-2 alone (14.6% ± 3.7%). Compound 1a was active at the reported concentrations (Table 1) (Boë dec et al., 2008) . Interestingly, the POM prodrug (compound 1b) was much more potent (57.7% ± 9.3%, at 1 mM) than compound 1a and the activity approached the potency of HMBPP ( Figure 3A ). This is a key finding because it demonstrates a dramatic increase in activity through use of a phosphoantigen prodrug and supports an important role for intracellular delivery of phosphoantigens.
To examine further the activity of these compounds in stimulating human Vg9Vd2 T cells, compounds 1a (unprotected), 1b (two POM groups), 1c (one POM group; one methyl group), and 1d (two methyl groups) along with the known phosphoantigens HMBPP, IPP, and risedronate ( Figure 3B and Figure S1 available online) were tested in a dose response manner. As expected, HMBPP potently expanded Vg9Vd2 T cells when stimulated for 3 days. At all of the tested concentrations (0.001-10 mM), HMBPP significantly increased Vg9Vd2 T cell population ( Figure 3B ), where HMBPP at 0.01 mM reached the peak of Vg9Vd2 T cell expansion to 63.3% ± 7.0%, which was more than a 4-fold increase compared to IL-2 alone treatment (14.6% ± 3.8%). The half maximal effective concentration (EC 50 ) of HMBPP in our hands was 0.00051 mM (Table 1) .
Much higher levels of IPP are needed to trigger an IPP-specific Vg9Vd2 T cell response (Sireci et al., 2001 ). As expected, 1,000 mM IPP significantly expanded the Vg9Vd2 T cell population ( Figure S2 ). The EC 50 of IPP was 36 mM, approximately 70,000-fold less potent that HMBPP (Table 1 ). The nitrogen-containing bisphosphonate risedronate indirectly activates Vg9Vd2 T cell through inhibition of farnesyl diphosphate synthase and intracellular IPP accumulation (Thompson and Rogers, 2004) . Consistently, risedronate increased the Vg9Vd2 T cell population in total PBMC cultures compared to treatment with IL-2 alone. Risedronate reached maximal stimulation at 10 mM ( Figure S2 ). Risedronate at 1,000 mM, however, resulted in a significant reduction of the activity, most likely due to toxicity, similar to the effects observed with other nitrogen-containing bisphosphonates at concentrations above 100 mM (Miyagawa et al., 2001) . To assess this toxicity, we measured cell viability at the day 14 time point and calculated half maximal inhibitory concentration (IC 50 ) values for each compound (Table 1 ). The selectivity indexes of HMBPP and risedronate were 980 and 38, respectively.
Consistent with a previous study (Boë dec et al., 2008) , the sodium salt 1a at 10 mM significantly increased the proportion of Vg9Vd2 T cells in the presence of IL-2, with an EC 50 of 4 mM (Figure 3B ; Table 1 ). Because dimethyl phosphonates are metabolically stable (Serafinowska et al., 1995) , the dimethyl ester was predicted to be inactive and indeed compound 1d did not show any stimulatory effect ( Figure 3B ; Table 1 ). Replacing one of the methyl groups with a labile POM group decreased the EC 50 value to 0.5 mM (Table 1) , and this compound (1c) at 1 mM was able to expand Vg9Vd2 T cell population to 51.1 ± 6.7% compared to 18.4 ± 5.4% from treatment with the dimethyl ester 1d at 1 mM. Compound 1b, which contains two POM groups, was much more potent than compounds 1a, 1c, and 1d, providing an EC 50 value of 0.0054 mM.Compound 1b at 0.01 mM significantly expanded the Vg9Vd2 T cell population compared to IL-2 alone treatment and at 0.1 mM reached the peak of stimulation up to 62.9 ± 1.6% of Vg9Vd2 T cells in PBMC cultures, which was similar to the peak of Vg9Vd2 T cell expansion with 0.01 mM of the potent stimulator, HMBPP (63.3 ± 7.0%; EC 50 = 0.00051 mM) ( Figure 3B ; Table 1 ). The EC 50 of compound 1b for T cell expansion was $740x lower than that of compound 1a, illustrating the vast improvement in efficacy seen by intracellular phosphoantigen delivery.
Pivaloyloxymethyl-Containing Compound 1b Is a DirectActing Phosphoantigen
Risedronate is known to stimulate Vg9Vd2 T cell proliferation by inhibition of farnesyl diphosphate (FPP) synthase in the mevalonate pathway, which results in accumulation of IPP. To determine whether the stimulatory effect of compound 1b on Vg9Vd2 T cell proliferation could be caused by inhibition of FPP synthase and/ or other enzymes of the mevalonate pathway, expansion of Vg9Vd2 T cells by risedronate and compound 1b was compared in the presence or absence of lovastatin, which inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase upstream of FPP synthase and prevents the synthesis of IPP. Treatment with 10 mM lovastatin alone did not alter the proliferation of Vg9Vd2 T cells. In the presence of 10 mM lovastatin, the stimulatory effect of risedronate at 10 mM on Vg9Vd2 T cell proliferation was significantly reduced from 48.9 ± 20.9% to 10.6 ± 4.0%. However, the stimulatory effect of compound 1b on Vg9Vd2 T cell proliferation was not significantly affected in the presence of lovastatin ( Figure 3C ). The data demonstrate that prodrug 1b does not achieve its stimulatory effect by altering the mevalonate pathway, but rather functions by releasing a direct phosphoantigen.
Only Compound 1b Significantly Induces Vg9Vd2 T Cell Proliferation after 2-hr Stimulation Next, we assessed whether duration of the stimulation plays a role in the Vg9Vd2 T cell proliferation between different compounds. We hypothesized that enhanced uptake of compound 1b would require a shorter stimulation time for maximal effects. Cells were treated with 0.1 mM HMBPP, 0.1 mM compound 1b, 100 mM compound 1a, or 100 mM risedronate for either 2 hr or the standard 3 days, followed by IL-2 supplementation every 3 days until day 14. Flow cytometry analysis showed that all compounds significantly expanded the Vg9Vd2 T cell population when the cells were stimulated for 3 days. In contrast, only compound 1b was able to significantly stimulate Vg9Vd2 T cell proliferation following a 2 hr-pulse treatment ( Figure 3D ). These observations indicate that compound 1b is more effective in activating the Vg9Vd2 T cell population compared to all of the other compounds tested, including HMBPP.
The Butyrophilin 3A1 SPRY Associated Domain/sp1A/ Ryanodine Receptor Domain, B30.2, Domain Directly Binds Phosphoantigens It recently was reported that BTN3A1 is required for phosphoantigen detection by Vg9Vd2 T cells (Harly et al., 2012; Vavassori et al., 2013; Wang et al., 2013) . However, the exact region of BTN3A1 where phosphoantigens bind is a matter of debate (Vavassori et al., 2013; Wang et al., 2013) . Based on the 740x increase in activity of the bis-POM prodrug, we hypothesized that intracellular binding occurs, which is in contrast to the model of extracellular binding to the immunoglobulin-like V (IgV) (Vavassori et al., 2013) . To determine whether the BTN3A1-antigen complex forms intracellularly or extracellularly, we expressed the recombinant extracellular IgV domain, the intracellular sp1A/ryanodine receptor domain/ SPRY associated domain (PRY/SPRY) (B30.2) domain, and the butyrophilin 3A1 full intracellular domain (BFI) and purified the soluble proteins. First, we verified the conformations of the constructs by nuclear magnetic resonance (NMR), and, according to the nicely dispersed Most of the amide resonance frequencies for PRY/SPRY domain overlapped with the peaks in the spectra for BFI (presented overlaid in Figure S4 ). This suggests the structure of PRY/SPRY domain in isolated form and in the context of the full-length protein remains the same and that the 68-residue membrane proximal region does not interact with the PRY/SPRY domain intramolecularly. We performed ITC to measure the interactions between these three BTN3A1 constructs and HMBPP (Figure 4A) . While no binding was observed with the extracellular BTN3A1 IgV domain, both the intracellular PRY/SPRY (B30.2) domain and the BFI domain showed strong binding with dissociation constants (K d ) of 1.61 mM and 1.54 mM, respectively. The interaction of HMBPP with BTN3A1 was enthalpy-driven with an unfavorable entropy change. HMBPP binding to the full intracellular domain (DH = À51.9 kJ/mol and TDS = À18.7 kJ/mol) and the PRY/SPRY domain (DH = À49.4 kJ/mol and TDS = À16.4 kJ/mol) shares very similar enthalpy and entropy terms, which reveals the binding site on BTN3A1 for phosphoantigens is enclosed in the PRY/SPRY domain (Table S1 ). and the PRY/SPRY domain ( Figure 5B ) and reached saturation at an HMBPP:protein ratio of 3:1. Combining ITC and NMR data, we have demonstrated that HMBPP interacts with BTN3A1 at its intracellular domain at 1:1 ratio and is likely capable of inducing significant conformational rearrangements in the intracellular domain of BTN3A1.
To determine whether binding was specific to HMBPP or a general property of phosphoantigens, we also tested whether another potent phosphoantigen, (5-hydroxy-4-methylpent-3-enyl)-phosphonooxyphosphinic acid (C-HDMAPP) could bind to internal domain ( Figure S2 ). C-HDMAPP is a phosphonate analog of HBMPP (Boë dec et al., 2008) . Interestingly, C-HDMAPP exhibited similar energetics relative to HMBPP when binding to the PRY/SPRY domain (K d = 1.95 mM, DH = À47.1 kJ/mol, TDS = À14.5 kJ/mol). The data reveal that both HMBPP and C-HDMAPP bind with high affinity to the intracellular PRY/SPRY (B30.2) domain, but not the extracellular V domain. C-HDMAPP has a slightly weaker interaction, which is consistent with its activity in cellular assays (Boë dec et al., 2008) . Therefore, we have demonstrated that two different phosphoantigens bind strongly to the intracellular domain of BTN3A1.
Because IPP also acts as a direct phosphoantigen in cellular assays, we tested its ability to interact with BTN3A1. However, we were unable to measure directly the binding of IPP to BTN3A1 by ITC. This is perhaps not surprising; given that the activity in cellular assays is approximately 71,000-fold less for IPP relative to HMBPP (Table 1) , making the projected dissociation constant well outside of the detection limit of ITC. Therefore, we performed a competition ITC study to determine whether increasing concentrations of IPP would affect the binding of HMBPP to BTN3A1 ( Figure S4 ). IPP dose-dependently decreased the favorable enthalpy of HMBPP binding from a DH of À51.9 kJ/mol to À47.7 kJ/mol and À38.7 kJ/mol at IPP:BTN3A1 ratios of 10:1 and 100:1, respectively (Table S1 ). IPP also dose-dependently made more favorable the TDS term of HMBPP binding, changing it from À18.7 kJ/mol to À12.7 kJ/ mol and À6.78 kJ/mol at IPP:BTN3A1 ratios of 10:1 and 100:1 respectively. Taken together, the data show that IPP binds to BTN3A1 with a much weaker affinity compared to HMBPP and that both compounds compete for the same binding site within the PRY/SPRY domain.
Because compound 1b is expected to undergo metabolic cleavage, resulting in accumulation of compound 1a, we examined the binding affinity between compound 1a and the BTN3A1 PRY/SPRY domain. Like IPP, the binding affinity of 1a was undetectable in ITC when using compound 1a as the sole ligand, as we had purposely chosen a weak phosphoantigen for the prodrug studies. However, as expected, compound 1a had a markedly stronger effect on the HMBPP binding to the PRY/SPRY domain relative to IPP ( Figure 4B ). Like IPP, compound 1a dose-dependently decreased the favorable enthalpy of HMBPP binding to BTN3A1. These effects also were measured at 1a:BTN3A1 ratios of 0:1(DH of À51.9 kJ/mol), 10:1 (À49.1 kJ/ mol), and 100:1 (À28.5 kJ/mol). Compound 1a also dose-dependently made more favorable the TDS term of HMBPP binding at IPP:BTN3A1 ratios of 10:1 (À16.2 kJ/mol) and 100:1 (+5.19 kJ/ mol). These data fit well with the cellular data in that 1a is a more potent phosphoantigen relative to IPP and would be expected to have a stronger effect. Perhaps surprisingly, the entropy term became positive at the highest concentration of 1a. This finding demonstrates that the prenyl alcohol and/or the olefin position play a more important role in the phosphoantigen-BTN3A1 interaction as compared to the distal phosphate group. Thus, according to ITC data, compound 1a may induce conformational changes in the intracellular domain of BTN3A1 similar to the ones induced by the stronger interaction with HMBPP and absent in the interface with IPP.
To confirm that IPP and compound 1a do have direct interactions with the intracellular domain of BTN3A1, 1 H-15 N HSQC titrations of IPP and compound 1a into BFI were performed at ligand:protein molar ratios of 0:1, 10:1, and 100:1. Both IPP ( Figure S6A ) and compound 1a ( Figure S6B ) showed concentration-dependent perturbations in the spectra. These two sets of titration data demonstrate that both IPP and compound 1a bind to BFI at a similar binding site with only a limited number of distinct differences in amide chemical shift perturbations between the two. In addition, the spectrum of compound 1a, but not IPP, shows several chemical shift perturbations identical to the ones observed in the titration of HMBPP (marked by arrows on Figure S6C ). Thus our NMR and ITC results are mutually consistent and suggest that binding sites for IPP and compound 1a on the PRY/SPRY domain are quite similar, although each compound is also involved in unique interactions with BTN3A1.
Prodrug 1b Stimulates Lysis of Daudi Lymphoma Cells by Vg9Vd2 T Cells
To examine if compound 1b can induce T cell killing of malignant cells, we examined the extent of Vg9Vd2 T cell lysis of Daudi lymphoma cells. Daudi cells were labeled with a fluorescent cell membrane dye and mixed with purified Vg9Vd2 T cells at a ratio of 5 to 1. Following coculture in the presence or absence of 0.1 mM test compounds, cells were stained with fluorescein isothiocyanate (FITC)-Annexin V antibody and the cell profiles examined by flow cytometry. The Vg9Vd2 T cells in combination with compound 1b resulted in a significant increase in Annexin V positive Daudi cells in comparison to no phosphoantigen treatment ( Figure 6A ). Of the test compounds, only HMBPP and compound 1b resulted in significant increase in Annexin V positive Daudi cells ( Figure 6B ), with compound 1b promoting greater T cell cytotoxic activity than HMBPP. In the absence of T cells, no effect on the viability of Daudi cells was observed when the cells were treated with high concentrations of either compound 1a or 1b ( Figure 6C ) for up to 72 hr at 10 mM. In contrast, cell viability was significantly reduced when treated with vorinostat.
DISCUSSION
In this study we have described the synthesis and evaluation of a phosphoantigen prodrug. Surprisingly, this compound exhibits a large increase in potency relative to the free phosphoantigen and displays similar, if not greater, potency relative to HMBPP. Additionally, our analysis of the newly synthesized POM-modified prodrug highlights several important conclusions ( Figure 6D ) about the mechanisms that underlie phosphoantigen presentation: (1) phosphoantigen charge serves as a barrier to both cellular entry and exit, (2) phosphoantigens bind to the intracellular, and not extracellular, domain of BTN3A1, and (3) effective delivery of phosphoantigens to the cytoplasm of malignant cells induces their lysis by Vg9Vd2 T cells. At the start of our studies, the molecular target of phosphoantigens was not known, so we had deliberately chosen to combine a moderate strength phosphoantigen with a well characterized prodrug to ensure that we could measure any potency increases generated by the prodrug strategy. To that end, it was quite surprising to see that compound 1b rivals the potency of HMBPP, the most potent known phosphoantigen. Additionally, relative to the free phosphonic acid 1a, the pivaloyloxymethyl prodrug 1b is approximately 750 times more potent for expansion of Vg9Vd2 T cells from peripheral blood following a three day stimulation (Table 1) . The increased activity is even more prevalent in assays using shorter incubation times ( Figure 3D ), such as the two hour PBMC stimulation or the four hour Daudi lysis assay ( Figure 6B ). In both of these assays, strong activity was seen with 0.1 mM of compound 1b, while the activity of the free phosphonic acid 1a at this concentration was not measureable. Table S1 .
These results demonstrate that phosphoantigen neutralization dramatically decreases the time necessary for loading phosphoantigen presenting cells and suggest that charged phosphoantigens enter cells primarily by active uptake rather than passive diffusion. There is clearly an opportunity for further increases in potency, which could be generated either though utilizing stronger phosphoantigens as templates or through utilizing different prodrug motifs.
During the course of these studies, two groups reported binding of phosphoantigens to BTN3A1 via conflicting mechanisms (Sandstrom et al., 2014; Vavassori et al., 2013) . Initially, De Libero and colleagues (Vavassori et al., 2013 ) demonstrated extracellular binding, whereas a recent paper by Adams (Sandstrom et al., 2014) clearly showed intracellular binding. Our studies are in strong agreement with those from the Adams Laboratory. In addition to the calorimetry assay, we also see strong interactions as assessed by NMR spectroscopy. Our results also demonstrate the relative contribution of the prenyl alcohol group and/or olefin position is more important than the second phosphate group, because binding of HMBPP to BTN3A1 is more strongly affected by 1a than IPP. Additionally, we have compared the effects of different antigen binding on the full intracellular domain and the PRY/SPRY domain by NMR. Our results indicate that although the binding site for phosphoantigens is localized in PRY/SPRY domain, the 68-residue membrane proximal region, preceding PRY/SPRY, also undergoes major structural rearrangement upon binding ( Figure 5C ). In the future, it will be interesting to determine the molecular details and the role of the lipid bilayer in this process. While we are still in process of resonance assignments, which can be time consuming for a protein of this size, our data are consistent with the recently published crystal structure of the PRY/SPRY domain in complex with HMBPP (Sandstrom et al., 2014) . Our findings clearly promote a model in which intracellular binding of phosphoantigens to BTN3A1 induces a conformational change, which either propagates across the membrane to the extracellular region or promotes an interaction with another intracellular protein, thus allowing new transmembrane complex formation necessary for recognition by the Vg9Vd2 T cell receptor.
Phosphoantigen prodrugs such as these may ultimately become clinically useful. Currently, there has been only one direct phosphoantigen that has been tested in human clinical trials, 4-bromo-3-hydroxy-3-methylbutyl diphosphate (BrHPP) (Fournié et al., 2013) . In these trials, the initial stimulation led to an expansion of the Vg9Vd2 population, but this required large intravenous doses and was limited in subsequent cycles of therapy. This dosing regimen was likely a consequence of limited plasma stability of BrHPP (a diphosphate), because studies in primates demonstrated rapid degradation in the plasma (Sicard et al., 2005) . Our results clearly show a time dependency to the uptake of phosphoantigens by peripheral blood cells, with no activation seen with HMBPP treatment of two hours ( Figure 3D ). This explains the fact that a very high concentration of BrHPP was needed to see any activation of Vg9Vd2 T cells in these patients. We have shown that the phosphoantigen prodrug 1b requires a much shorter incubation time. Therefore, this or other Compared to the PRY/SPRY domain, the full-length intracellular domain of BTN3A1 (BFI) includes an additional membrane-proximal region of 68 residues at the N terminus, which is demonstrated to be involved in the interaction with HMBPP and to undergo significant structural changes upon binding. (A) Chemical shift perturbations for the interaction of HMBPP and BFI at ratios of 0:1 (black), 1:1 (blue), and 3:1 (red). (B) Chemical shift perturbations for the interaction of HMBPP and the PRY/ SPRY domain at ratios of 0:1 (gray), 1:1 (orange), and 3:1 (green). (C) Evidence for the involvement of the 68-residues membrane-proximal region in interaction with HMBPP: HSQC spectra of the free BFI (black), BFI + HMBPP at 1:3 ratio (red), and PRY/SPRY + HMBPP at 1:3 ratio (green). Peaks that belong to the 68-residue membrane-proximal region are absent in the spectrum of PRY/SPRY domain. Arrows indicate the peaks corresponding to the amides from this region that have showed remarkable shifts upon binding to HMBPP, thus suggesting significant structural rearrangements. See also Figures S4-S6 . similar neutral compounds may be able to achieve Vg9Vd2 T cell activation in human blood with significantly lower doses relative to BrHPP.
Alternatively, others have used bisphosphonate drugs as phosphoantigens in clinical trials (Van Beek et al., 2002) ; however, these compounds also have severely restricted pharmacokinetics (e.g., rapid bone sequestration), low therapeutic indexes, and the potential for side effects such as osteonecrosis. Our data (Table 1) clearly show the advantage of using direct phosphoantigens over an indirect phosphoantigen, as HMBPP has a selectivity index that is 25 times greater than risedronate. It is not clear whether other nitrogenous bisphosphonates, such as zoledronate, have similarly narrow selectivity indexes. However, we presume this to be the case as both the stimulation and the cytotoxicity result from cellular inhibition of FPP synthase, and at least one other group, has reported that shorter durations of stimulation with zoledronate reduces its cytotoxic effects (Nussbaumer et al., 2013) . Compound 1b also has an improved selectivity index relative to risedronate, and again we believe it to be possible to make further gains in this area through compound optimization.
Finally, it is important to note the functional consequences of the phosphoantigen prodrug in the inducible lysis of cancer cells (Figure 6 ). Compound 1b causes no discernable growth inhibition of Daudi cells at concentrations up to 10 mM and treatment times up to 72 hr. However, when combined with Vg9Vd2 T cells, compound 1b can induce the lysis of Daudi cells at 0.1 mM in only four hours. Therefore, we believe that compounds such as 1b, if effectively delivered to malignant cells, have the potential for strong chemically induced cancer immunotherapy through recruiting a targeted Vg9Vd2 T cell response.
In conclusion, these findings reveal several key mechanisms of antigen recognition in the immune system and point to new possibilities for development of clinical agents through understanding phosphoantigen structure activity relationships at the molecular and cellular levels.
SIGNIFICANCE
We have described a phosphoantigen prodrug that functions with exquisite potency. The prodrug defines key roles of phosphoantigen charge, binding, and delivery. This strategy has potential to impact clinical use of phosphoantigens, which have been limited by poor pharmacokinetics, for treatment or prevention of cancer and infectious disease.
EXPERIMENTAL PROCEDURES Chemical Synthesis Compound 4
To a stirred solution of n-BuLi (2.4 M in hexanes, 14.6 ml, 35.0 mmol) in tetrahydrofuran at À78 C was added N,N-diisopropyl amine (4.82 ml, 34.4 mmol).
The resulting solution was allowed to stir for 10 min and dimethyl methylphosphonate (3.7 ml, 34.1 mmol) was added slowly via syringe. Once addition was complete, the mixture was allowed to stir for 15 min during which time a white precipitate formed. Prenyl bromide 3 (5.17 g, 34.7 mmol) was added slowly via syringe, and after addition was complete the solution was allowed to stir for an additional 30 min at -78 C, allowed to warm to room temperature unassisted, and stirred overnight. A saturated aqueous solution of NH 4 Cl was added, the solution was extracted with Et 2 O, and the combined extracts were dried (Na 2 SO 4 ) and concentrated in vacuo. 
Compound 1a
Compound 1d (0.166 g, 0.80 mmol) was dissolved in CH 2 Cl 2 , and the mixture was cooled to 0 C in an ice bath. Collidine (0.425 ml, 3.2 mmol) and bromotrimethylsilane (0.419 ml, 3.2 mmol) were added via syringe, and the reaction was allowed to stir overnight. After the volatiles were removed, toluene was added and removed in vacuo, and this cycle was repeated three times providing a white solid. The solid was dissolved in an aqueous NaOH (1.49 M, 2.15 ml, 3.2 mmol), and the reaction mixture was stirred overnight. The mixture was poured into an equal volume of acetone and cooled at 7 C for a period of 24 hr to facilitate precipitation. Acetone and H 2 O were removed in vacuo, the resulting solid was washed with acetone, dissolved in H 2 O, and washed with diethyl ether. The aqueous phase was decolorized using activated charcoal and concentrated in vacuo to provide the target salt in 77% yield (137 mg Phosphonate 4 (0.967 g, 5.0 mmol), sodium iodide (1.56 g, 10.4 mmol), and pivaloyloxymethyl chloride (2.3 ml, 15.9 mmol) were added to acetonitrile under an atmosphere of argon. The mixture was heated and held at reflux with vigorous stirring overnight. Water and diethyl ether were added, and the phases were separated. The aqueous phase was extracted with diethyl ether, and the combined organic extracts were dried (Na 2 SO 4 ) and concentrated in vacuo. Final purification by flash column chromatography (30% 
Vg9Vd2 T Cell Isolation and Culture
Human peripheral blood mononuclear cell (PMBCs) were isolated from blood from Research Blood Components using density centrifugation. Cells were frozen in freezing media (10% DMSO, 90% fetal bovine serum [FBS] ) in liquid nitrogen until needed. 2À4 3 10 6 cells were resuspended in fresh T cell media (RPMI-1640, 10% heat-inactivated FBS, 1x 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, pyruvate, nonessential amino acids, b-mercaptoethanol [BME]) and added to 6-well plates. Cells were stimulated for 3 days unless stated otherwise. Cells were cultured for another 11 days after compound removal. Human IL-2 (5 ng/ml) was supplemented every 3 days. All experiments were performed at least three times independently using at least two different blood donors.
Flow Cytometry
Cells were washed and suspended in 100 ml of fluorescence-activated cell sorting buffer (2% BSA in PBS). Total gamma delta T cell receptor (TCR) was labeled using either FITC-anti-human Pan gamma delta TCR antibody or anti-human Pan gamma delta TCR antibody followed by peridinin chlorophyll-eFluor 710-anti-mouse immunoglobulin G1. Cells were costained with PE-conjugated anti-human CD3. Each step was done at 4 degrees for 30 min, washed twice, and then fixed in 3% paraformaldehyde before flow analysis. Data were analyzed using FlowJo.
Cloning and Purification of Butyrophilin 3A1 Constructs BTN3A1 constructs were purified based on the method that De Libero and colleagues (Vavassori et al., 2013) with some modifications (see Supplemental Experimental Procedures).
Isothermal Titration Calorimetry
Calorimetric measurements of BTN3A1 domains were performed on a low volume Nano ITC. All experiments were carried out in a buffer of 50 mM Tris, pH 7.5, 100 mM NaCl, 5 mM BME at 25 C with a stirring speed of 200 rpm to minimize the precipitation. Each titration consisted of twenty 2.5 ml injections with 300 s time intervals. The concentrations of protein samples were determined by UV, and the compounds were prepared in the same buffer from the dilution of 10 mM or 100 mM stock. The protein concentration ranged from 30 mM to 60 mM. The concentration of protein was examined after each ITC experiment and a good solubility (>85%) was shown. Data analysis was done in NanoAnalyze Software suite using an ''independent'' model. In all cases, a stoichiometry of 1 ± 0.1 was revealed.
Nuclear Magnetic Resonance Spectroscopy
15
N-labeled recombinant proteins were overexpressed in M9 medium supplemented with 15 NH 4 Cl as the sole nitrogen source and purified as above. NMR samples of 100-200 mM were prepared in a buffer of 50 mM Tris, pH 7.5, 100 mM NaCl, 5 mM BME, 7% D 2 O, 1 mM 4,4-dimethyl-4-silapentane-1-sulfonic acid as the internal standard. C. All spectra were processed with NMRPipe (Delaglio et al., 1995) and analyzed in CcpNmr Analysis (Vranken et al., 2005) software suite.
Daudi Killing Assay
The Daudi killing assay was performed based on (Gomes et al., 2010) with slight modification. Vg9Vd2 T cells were expanded from PMBCs by stimulation with 0.01 mM HMBPP for 3 days and expansion for 8À11 additional days as above.
At that time, Vg9Vd2 T cells were purified by negative selection using a kit.
Resulting populations were typically 98%À99% Vg9Vd2 T cells as assessed by flow cytometry. Daudi cells were stained with DiD (2 min in 4 mM DiD in BSA/PBS), quenched by addition of an equal volume of FBS, and washed twice in T cell media. Daudi cells (6 3 10 3 ) were mixed with 3 3 10 4 T cells and test compounds to a final volume of 100 ml. Mixtures were incubated for 4 hr at 37 degrees then placed on ice for 5 min. Annexin V FITC (3 ml) was added for 15 min on ice, then cells were diluted by addition of 200 ml binding buffer (Becton Dickinson) and immediately analyzed by flow cytometry.
Proliferation Assay
Daudi proliferation was performed as described with the following parameters (Wiemer et al., 2013) . Cells/well (10,000) were added to 96-well plates in 100 ml in the presence of test compounds. Cells were allowed to proliferate for 72 hr. During the last 2 hr, cells were labeled with 5 ml of CellQuantiBlue reagent and were scanned with a Victor plate reader.
Statistical Analysis
One-way ANOVA was used to calculate significance. Comparisons were done relative to the control or between pairs of conditions. Columns in bar graphs represent the mean ± SD. An a level of 0.05 was used. 
SUPPLEMENTAL INFORMATION
